Interim analysis enrollment target reached on time in Phase II breast cancer study

AmeRuss is happy to announce that the global enrollment of the study of approved combination of study drugs for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer which has progressed following prior therapy reached its interim analysis milestone on time.

This is an open label, randomized, multicenter, phase II study to explore the potential benefit of the prophylactic use of the study drug in the prevention or reduction of diarrhea associated with treatment with antitumor drugs.

Participating countries include: Czech Republic, Hong Kong, Israel, Italy, Poland, Russia and United Kingdom.

Russia is represented by 8 sites in Central, Ural and Siberia regions.

Cumulative Global Enrollment – 62 Patients enrolled as of 13 January 2016. This is an 87% from globally targeted 140 enrolled Patients. Thirty-five ┬ápatients have been enrolled in Russia. Global enrollment is currently halted due to the interim analysis.

Related News